The mode of progressive disease affects the prognosis of patients with metastatic breast cancer
Open Access
- 14 August 2018
- journal article
- research article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 16 (1) , 1-6
Abstract
According to the Response Evaluation Criteria in Solid Tumors (RECIST), progressive disease (PD) is diagnosed under two conditions: an increase in size of pre-existing lesions (IS) and the appearance of new lesions (NL). We retrospectively investigated the difference in the prognosis between IS and NL. Patients receiving drug therapies for metastatic breast cancer between 2004 and 2015 at our institution were reviewed. The survival time after NL and IS was compared and the frequency of NL with each drug calculated. For the 107 eligible patients, the survival time after NL at second-line chemotherapy was significantly worse than after IS (median survival time 4.3 months vs. 20.3 months, p = 0.0048). Maintenance therapy with bevacizumab or trastuzumab had a high frequency of NL (88.9%), and third-line eribulin had a low frequency of NL (16.7%). A multivariate analysis showed that NL at second-line chemotherapy was not an independent risk factor (hazard ratio 1.02, 95%; confidence interval 0.54–1.93, p = 0.95) for the total survival time. Patients with IS had a better survival after PD than those with NL. We may be able to avoid changing drug therapy for patients without NL and allow them to continue drug therapy for longer.Keywords
This publication has 9 references indexed in Scilit:
- “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyBreast Cancer Research, 2015
- The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 databaseEuropean Journal of Cancer, 2014
- Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 TrialEuropean Urology, 2013
- The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapyAnnals of Oncology, 2011
- Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsJournal of Clinical Oncology, 2011
- Fifteen-year trends in metastatic breast cancer survival in GreeceBreast Cancer Research and Treatment, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancerCancer, 2007
- Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1996